Item 1.01 - Entry into a Material Definitive Agreement.
During the period December, 2021 to October, 2022,
The funding provided by AD Pharma enables the Company to continue operations to
late
There can be no assurance we will be successful entering into and receiving additional financing. In the absence of the receipt of additional financing, we will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. This could result in a complete loss of shareholder value in the Company. Even assuming we are successful in securing additional sources of financing to fund continued operations, there can be no assurance that the proceeds of such financing will be sufficient to fund operations until such time, if at all, that we generate sufficient revenue from our products and product candidates to sustain and grow our operation.
The inclusion of a description of the Note under Item 1.01 of this Current Report on Form 8-K shall not be deemed an acknowledgement that the Note is a material agreement not made, or deemed not to be made, in the ordinary course of our business.
At
Item 2.03 - Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The contents of Item 1.01 are incorporated herein by reference.
Forward-Looking Statements
Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.
2
Forward-looking statements may include, but are not limited to:
· our ability to fund or obtain funding for our continuing operations, including
the development of our products utilizing our LIMITx and IMPEDE technologies;
· whether we will receive FDA acceptance for an NDA for LTX-03 by the target
date;
· whether our licensees will terminate the license prior to commercialization;
· the expected results of clinical studies relating to LTX-03 or any successor
product candidate, the date by which such studies will complete and the results will be available and whether any product candidate will ultimately receive FDA approval;
· the ability of LTX-03 single tablets to achieve bioequivalence or to
demonstrate efficacy in a clinical study;
· whether our licensing partners will develop any additional products and utilize
Acura for such development;
· whether LIMITx will retard the release of opioid active ingredients as dose
levels increase;
· whether the extent to which products formulated with the LIMITx technology
mitigate respiratory depression risk will be determined sufficient by the FDA;
· our and our licensee's ability to successfully launch and commercialize our
products and technologies;
· our and our licensee's ability to obtain necessary regulatory approvals and
commercialize products utilizing our technologies;
· the market acceptance of, timing of commercial launch and competitive
environment for any of our products;
· our ability to develop and enter into additional license agreements for our
product candidates using our technologies;
· the ability to avoid infringement of patents, trademarks and other proprietary
rights of third parties;
· the ability of our patents to protect our products from generic competition and
our ability to protect and enforce our patent rights in any paragraph IV patent
infringement litigation;
· the adequacy of the development program for our product candidates, including
whether additional clinical studies will be required to support an NDA and FDA
approval of our product candidates;
· changes in regulatory requirements;
· adverse safety findings relating to our commercialized products or product
candidates in development;
· whether or when we are able to obtain FDA approval of labeling for our product
candidates for the proposed indications and whether we will be able to promote
the features of our technologies; and
· whether our product candidates will ultimately perform as intended in
commercial settings.
In some cases, you can identify forward- looking statements by terms such as
"may," "will", "should," "could," "would," "expects," "plans," "anticipates,"
"believes," "estimates," "indicates", "projects," "predicts," "potential" and
similar expressions intended to identify forward-looking statements. These
statements reflect our current views with respect to future events and are based
on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these forward-looking
statements. We discuss many of these risks in greater detail in our filings with
the
3
© Edgar Online, source